Daunorubicin盐酸柔红霉素,23541-50-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Daunorubicin hydrochloride

CAS No. : 23541-50-6

MCE 国际站：Daunorubicin hydrochloride

产品活性：Daunorubicin (Daunomycin) hydrochloride 是一种拓扑异构酶 II (topoisomerase II) 抑制剂，具有有效的抗肿瘤活性。Daunorubicin hydrochloride 抑制 DNA 和 RNA 合成 (DNA and RNA synthesis)。Daunorubicin hydrochloride 是一种细胞毒素，可抑制癌细胞活力并诱导细胞凋亡 (apoptosis) 和坏死 (necrosis)。Daunorubicin hydrochloride 还是一种蒽环类抗生素。Daunorubicin hydrochloride 可用于研究感染和多种癌症，包括白血病、非霍奇金淋巴瘤、尤文氏肉瘤、维尔姆斯氏瘤。

研究领域：Cell Cycle/DNA Damage  |  Antibody-drug Conjugate/ADC Related  |  Anti-infection  |  Autophagy  |  Apoptosis

作用靶点：Topoisomerase  |  DNA/RNA Synthesis  |  ADC Cytotoxin  |  Bacterial  |  Autophagy  |  Apoptosis  |  Antibiotic

In Vitro: Daunorubicin hydrochloride (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells.
Daunorubicin hydrochloride (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells.
Daunorubicin hydrochloride (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells.
Daunorubicin hydrochloride (0.4 μM, 120 min) induces ROS generation in L3.6 cells.
Daunorubicin hydrochloride (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line).

In Vivo: Daunorubicin hydrochloride (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats.
Daunorubicin hydrochloride (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice.

相关产品：Covalent Screening Library Plus  |  Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Toxins for Antibody-Drug Conjugate Research Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antibacterial Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  Phenols Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Blood Cancer Compound Library  |  Microbial Metabolite Library  |  Targeted Diversity Library  |  Tumorigenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  Anti-Cancer Natural Product Library  |  Chemotherapy Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Cell Death Library  |  MG-132  |  Rapamycin  |  Cycloheximide  |  Chloroquine  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Dexamethasone  |  Acetylcysteine  |  Puromycin dihydrochloride  |  Angiotensin II human  |  Dimethyl sulfoxide  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  G-418 disulfate  |  Temozolomide  |  Rotenone  |  Mdivi-1

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds